Skip to main content
BL Pharmtech Corp. logo

BL Pharmtech Corp. — Investor Relations & Filings

Ticker · 065170 ISIN · KR7065170003 KO Manufacturing
Open in API
Filings indexed 278 across all filing types
Latest filing 2024-08-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 065170

About BL Pharmtech Corp.

http://www.blpharmtech.com/

BL Pharmtech Corp. is a healthcare company that manufactures, distributes, and sells health functional foods, dietary supplements, and nutraceuticals. The company's portfolio also includes cosmetics, food additives, and pharmaceuticals. A significant part of its operations is dedicated to biotechnology and bio-pharmaceutical research and development. Through its Daedeok Research Institute and in collaboration with subsidiaries BL Melanys and BL Science, the company partners with academic institutions, including KAIST and Columbia University Medical Center, to advance its research initiatives.

Recent filings

Filing Released Lang Actions
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Semi-Annual Report' (반기보고서) for the company 'BL Pharmtech' (주식회사 비엘팜텍) covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial information, business overviews, and management reports, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-14 Korean
[기재정정]타법인주식및출자증권취득결정
M&A Activity Classification · 1% confidence The document is a regulatory filing from a Korean company (B-L Pharmtech) regarding the acquisition of shares in another company (Anyone F&C). It specifically details a 'Correction Report' (정정신고) for a previous 'Decision to Acquire Shares and Securities of Another Corporation' (타법인주식및출자증권취득결정). This type of filing is a standard corporate disclosure regarding M&A or investment activity, which falls under the 'RNS' (Regulatory Filings) category as it is a specific regulatory announcement of a corporate action.
2024-07-26 Korean
전환가액의조정
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the adjustment of the conversion price for convertible bonds (CB) issued by Biopharmtech. It details the change in conversion price, the number of shares, and the underlying calculation methodology based on market price fluctuations. This falls under capital structure changes and financing updates, specifically related to convertible securities adjustments, which is best categorized as CAP (Capital/Financing Update).
2024-05-30 Korean
[기재정정]분기보고서 (2024.03)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the company '주식회사 비엘팜텍' (BL Pharmtech Corp.) for the first quarter of 2024. It explicitly states it is a '정정신고' (Correction Report) for the previously submitted 1st Quarter Report. It contains detailed financial tables, including consolidated and separate financial statements, notes on financial assets, and company overview information. Since it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2024
2024-05-20 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'BL Pharmtech' (주식회사 비엘팜텍) covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial information, business operations, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-16 Korean
최대주주변경
Major Shareholding Notification Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a change in the largest shareholder of the company 'Biol Pharmtech'. It details the transfer of shares, the identity of the new major shareholder, and the purpose of the acquisition (management participation). This type of disclosure is a standard regulatory requirement for significant changes in corporate control and ownership structure, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Major Shareholding Notification' (which usually refers to 5% rule filings) or 'Director's Dealing' (which refers to individual insider trades).
2024-03-28 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.